Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01449)
Name
Sulfanilamide
Synonyms    Click to Show/Hide the Synonyms of This API
sulfanilamide; 4-Aminobenzenesulfonamide; 63-74-1; Sulphanilamide; Sulfamine; Sulfonamide; Sulphonamide; Sulfonylamide; p-Aminobenzenesulfonamide; Prontosil Album; Bacteramid; Streptasol; p-Sulfamoylaniline; Sulfonamide P; p-Aminobenzenesulfamide; Benzenesulfonamide, 4-amino-; Estreptocida; Exoseptoplix; Streptoclase; p-Sulfamidoaniline; Prontylin; Sulfamidyl; Sulfanalone; Sulfanidyl; Sulfanil; Sulfocidine; Sulfana; Sulfanilimidic acid; p-Anilinesulfonamide; p-Aminophenylsulfonamide; 4-Aminobenzene-1-Sulfonamide; Ambeside; Antistrept; Astreptine; Astrocid; Bactesid; Collomide; Colsulanyde; Copticide; Deseptyl; Ergaseptine; Erysipan; Gombardol; Lysococcine; Neococcyl; Orgaseptine; Prontalbin; Proseptal; Proseptine; Proseptol; Pysococcine; Septanilam; Septinal; Septolix; Septoplex; Septoplix; Strepamide; Strepsan; Streptagol; Streptamid; Streptamin; Streptocid; Streptocide; Streptocom; Strepton; Streptopan; Streptosil; Streptozol; Streptozone; Streptrocide; Sulfocidin; Therapol; 4-Sulfamoylaniline; Albexan; Albosal; Dipron; Gerison; Infepan; Sanamid; Stramid; Tolder; Lusil; Prontosil White; Pronzin Album; Septamide Album; Stopton Album; Streptocid album; Prontosil I; Rubiazol A; White streptocide; PABS; Streptocide White; p-Aminobenzenesulfonylamide; 4-Aminophenylsulfonamide; Fourneau 1162; Sulfanilamide Vaginal Cream; Aniline-p-sulfonic amide; Benzenesulfonamide, p-amino-; 4-azanylbenzenesulfonamide; 4-Amino-benzenesulfonamide; MFCD00007939; p-Aminobenzensulfonamide; 1162 F; para-aminobenzenesulfonamide; A-349; F 1162; UNII-21240MF57M; CHEBI:45373; 4-aminobenzene sulfonic acid amide; CHEMBL21; p-amino benzene sulfonamide; Streptocidum; NSC7618; 21240MF57M; CAS-63-74-1; NCGC00016285-02; NCGC00016285-05; Sulfanilamida; Sulfanilamidum; Sulfanilamide-13C6; Sulfanilamide, >=99%; DSSTox_CID_3622; DSSTox_RID_77115; DSSTox_GSID_23622; Streptocide (VAN); Solfanilamide [DCIT]; Caswell No. 809A; Solfanilamide; HSDB 223; Sulfanilamidum [INN-Latin]; Sulfanilamida [INN-Spanish]; SMR000059035; CCRIS 764; SR-01000763435; NSC 7618; EINECS 200-563-4; EPA Pesticide Chemical Code 077902; BRN 0511852; sulfanilamine; Sulfanimide; Sulfanilamide [INN:DCF:NF]; AI3-00952; sulphanilic amide; 4-sulphanilamide; Sulfanimide,(S); Streptocid (TN); delta-Sulfanilamide; Prestwick_36; 4-sulfamoyl-aniline; sulfanilamide reagent; sulfanilamide-reagent; 4-sulphamoyl aniline; Sulfanilamide (INN); Sulfanilamide, 98%; AVC; Spectrum_000489; 4-aminobenzensulfonamide; WLN: ZSWR DZ; 4-(Aminosulfonyl)aniline; 4-aminobenzenesulphonamide; p-aminobenzene sulfonamide; Prestwick0_000729; Prestwick1_000729; Prestwick2_000729; Prestwick3_000729; Spectrum2_000846; Spectrum3_001406; Spectrum4_000398; Spectrum5_001081; 4-aminobenzene sulfonamide; 4-aminobenzene-sulfonamide; ACMC-1AYS4; p-aminosulfonyl phenylamine; SCHEMBL740; 4-amino-benzenesulphonamide; Epitope ID:122232; AVC (TN); Oprea1_273157; p-aminobenzene sulfonyl amide; BSPBio_000658; BSPBio_003052; KBioGR_000955; KBioSS_000969; 4-14-00-02658 (Beilstein Handbook Reference); MLS001074682; MLS002152940; BIDD:GT0170; DivK1c_000528; SPECTRUM1500646; SPBio_000831; SPBio_002597; aromatic sulfonamide compound 5; BPBio1_000724; halogenosulfanilamide deriv. 5a; ZINC2101; (4-(Aminosulfonyl)phenyl)amine; DTXSID4023622; SCHEMBL11880061; BDBM10857; HMS501K10; KBio1_000528; KBio2_000969; KBio2_003537; KBio2_006105; KBio3_002272; Sulfanilamide, p.a., 99.0%; NINDS_000528; Sulphanilamide-[d4] Hydrochloride; HMS1570A20; HMS1921O07; HMS2092E20; HMS2097A20; HMS2233B19; HMS3370J16; HMS3655K19; HMS3714A20; HMS3744M13; Pharmakon1600-01500646; Ro13354; EBD35543; HY-B0242; NSC-7618; Sulfanilamide Melting Point Standard; Tox21_110351; Tox21_201331; Tox21_303336; ANW-43069; aromatic/heteroaromatic sulfonamide 2; BBL005257; c1264; CCG-40302; NSC757404; s1685; SBB008928; STK298902; AKOS000119305; Tox21_110351_1; DB00259; MCULE-8746683155; NSC-757404; IDI1_000528; NCGC00016285-01; NCGC00016285-03; NCGC00016285-04; NCGC00016285-06; NCGC00016285-08; NCGC00091144-01; NCGC00091144-02; NCGC00091144-03; NCGC00257174-01; NCGC00258883-01; AK-77666; AS-13239; BP-12552; H701; ST079295; Sulfanilamide (4-Aminobenzenesulfonamide); SY009959; SBI-0051575.P002; 4-Aminobenzenesulphonamide (Sulphanilamide); AB00052138; FT-0657032; FT-0674702; S0381; SW196353-3; Sulfanilamide, JIS special grade, >=99.7%; Sulfanilamide, Vetec(TM) reagent grade, 97%; C07458; D08543; M-3994; 36799-EP2272517A1; 36799-EP2272834A1; 36799-EP2289871A1; 36799-EP2301923A1; 36799-EP2301929A1; 36799-EP2301935A1; 36799-EP2305250A1; 36799-EP2305640A2; 36799-EP2305674A1; 36799-EP2305808A1; 36799-EP2311796A1; 36799-EP2311797A1; 36799-EP2311798A1; 36799-EP2311799A1; 36799-EP2311801A1; 91143-EP2295053A1; 91143-EP2305219A1; AB00052138-10; AB00052138_11; AB00052138_12; A834498; AC-907/25014139; Q423423; Sulfanilamide, VETRANAL(TM), analytical standard; SR-01000763435-2; SR-01000763435-3; SR-01000763435-4; F2190-0451; BENZENESULFONIC ACID,4-AMINO,AMIDE SULFANILAMIDE; Sulfanilamide, European Pharmacopoeia (EP) Reference Standard; Sulfanilamide, puriss. p.a., >=99% (calc. to the dried substance); Sulfanilamide, United States Pharmacopeia (USP) Reference Standard; Sulfanilamide Melting Point Standard, United States Pharmacopeia (USP) Reference Standard; Sulfanilamide melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material
Clinical Status
Approved
PubChem CID
5333
Formula
C6H8N2O2S
Canonical SMILES
C1=CC(=CC=C1N)S(=O)(=O)N
InChI
1S/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)
InChIKey
FDDDEECHVMSUSB-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5333"></iframe>
3D MOL is unavailable 2D MOL
Physicochemical Properties Molecular Weight 172.21 Topological Polar Surface Area 94.6
XlogP -0.6 Complexity 211
Heavy Atom Count 11 Rotatable Bond Count 1
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 4
Full List of Drug Formulations (DFMs) Containing This API
          Sulfanilamide 15% cream Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Lactose; Propylene Glycol; Stearic Acid; Diglycol Stearate; Methylparaben; Propylparaben; Trolamine; Water; Lactic Acid
                   Dosage Form Cream
                   Company Mylan Speciality
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
methylparaben DIG Info Carbonic anhydrase VII (Ki = 780 nM) [1]
Stearic acid DIG Info Phosphodiesterase 3A (IC50 = 3.1 uM) [2]
Propylparaben sodium DIG Info Estrogen receptor alpha (EC50 = 38200 nM) [3]
Trolamine DIG Info Choline acetylase (IC50 < 200000 nM) [4]
Lactic acid DIG Info Fetal lung MRC5 cells (IC50 = 23930 nM) [5]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [6]
References
1 Mono-/dihydroxybenzoic acid esters and phenol pyridinium derivatives as inhibitors of the mammalian carbonic anhydrase isoforms I, II, VII, IX, XII and XIV. Bioorg Med Chem. 2013 Mar 15; 21(6):1564-9.
2 The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
3 Discovery of natural estrogen receptor modulators with structure-based virtual screening. Bioorg Med Chem Lett. 2013 Jun 1; 23(11):3329-33.
4 Chemistry and biological activities of N,N-dimethylaminoethyl acrylate, a choline acetyltransferase inhibitor. J Med Chem. 1976 Feb; 19(2):300-3.
5 Design, synthesis and biological studies of a library of NK1-Receptor Ligands Based on a 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4H-pyran core: Switch from antagonist to agonist effect by chemical modification. Eur J Med Chem. 2017 Sep 29; 138:644-660.
6 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.